Alligator Bioscience AB

It looked like the writing was on the wall for Alligator Biosciences after the Swedish company slashed its workforce and ended its early-stage R&D activities at the end of last year but 2025 has s

Cash-strapped Alligator Biosciences is reducing its workforce and early-stage activities to put all its focus on preparing its pancreatic cancer candidate, mitazalimab, for Phase III trials. The Swedi

The future of Idogen AB hangs in the balance with the Swedish firm's critical financial situation leaving its lead clinical-stage development program IDO 8 for hemophilia in limbo. Idogen's announce

Horizon Therapeutics plc has scored a second win in its Phase II trial of dazodalibep in patients with Sjögren’s syndrome (SS) as the study has met its primary endpoint in another patient population,